Research programme: mitochondria derived peptides - CohBar
Alternative Names: CB-4209; Humanin - CohBar; MBTs - CohBar; MDPs - CohBar; Mitochondria-based therapeutics - CohBar; MOTS-c; MOTS-c analog - CohBar; SHLP 2; SHLP 6; Small humanin-like peptides - CohBarLatest Information Update: 28 Feb 2021
At a glance
- Originator Albert Einstein College of Medicine; University of Southern California
- Developer Albert Einstein College of Medicine; CohBar; University of Southern California
- Class Anti-ischaemics; Antidementias; Antihyperglycaemics; Antineoplastics; Cardiovascular therapies; Hepatoprotectants; Hormones; Neuroprotectants; Obesity therapies; Peptides; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Insulin receptor modulators; Lipolysis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Atherosclerosis; Cerebral ischaemia; Myocardial ischaemia; Neurodegenerative disorders; Non-alcoholic steatohepatitis; Obesity; Prostate cancer; Type 2 diabetes mellitus
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA
- 28 Feb 2021 No recent reports of development identified for preclinical development in Obesity(Prevention) in USA
- 28 Feb 2021 No recent reports of development identified for preclinical development in Prostate-cancer in USA